Menu
Search
|

Menu

Close
X

Novus Therapeutics Inc NVUS.OQ (NASDAQ Stock Exchange Capital Market)

3.78 USD
+0.53 (+16.31%)
As of Feb 17
chart
Previous Close 3.25
Open 3.27
Volume 2,844
3m Avg Volume 2,624
Today’s High 3.78
Today’s Low 3.25
52 Week High 8.46
52 Week Low 3.13
Shares Outstanding (mil) 6.94
Market Capitalization (mil) 33.47
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.459
FY16
-15.094
FY15
-18.049
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
1.43
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
1.05
16.52
LT Debt to Equity (MRQ)
vs sector
1.05
12.22
Return on Investment (TTM)
vs sector
-67.10
14.43
Return on Equity (TTM)
vs sector
-67.53
16.13

EXECUTIVE LEADERSHIP

Keith Katkin
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Catherine Turkel
President, Since 2017
Salary: --
Bonus: --
Gregory Flesher
Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jon Kuwahara
Senior Vice President - Finance and Administration, Since 2017
Salary: --
Bonus: --
Erez Chimovits
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

19900 Macarthur Blvd Ste 550
IRVINE   CA   92612-8426

Phone: +1949.2388090

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

SPONSORED STORIES